An interventional study of Trigger Point Injection + Home Exercise and Experimental: Myofascial Release + Home Exercise in Cervicogenic Headache, sponsored by Konya Beyhekim Training and Research Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Konya Beyhekim Training and Research Hospital · Not applicable, Interventional, and Treatment
Cervicogenic headache is a type of headache associated with problems in the neck. This study aims to compare the effects of trigger point injection, myofascial release, and their combination in patients with cervicogenic headache.
A total of 120 adults aged 18-65 years with cervicogenic headache are planned to be included and randomly assigned to one of four groups: trigger point injection with home exercises, myofascial release with home exercises, combined trigger point injection and myofascial release with home exercises, or home exercises alone.
Trigger point injections will be performed using 0.5% lidocaine once weekly for four sessions. Myofascial release will also be provided once weekly for four sessions in the relevant groups. The home exercise program will include neck range-of-motion exercises, stretching, and is
197 studies on the registry are indexed under Post-Traumatic Headache; 53 are open to participants now.
This study's planned enrollment of 120 is above the median of 44 across 173 interventional studies indexed under Post-Traumatic Headache.
Browse Post-Traumatic Headache studies →Konya Beyhekim Training and Research Hospital is the lead sponsor of 32 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive trigger point injections using 0.5% lidocaine once weekly for four sessions. The injections will be administered to active trigger points in the upper trapezius, sternocleidomastoid, and splenius capitis muscles, as appropriate. Participants will also perform a home exercise program consisting of neck range-of-motion exercises, trapezius stretching, and isometric neck strengthening exercises.
Drug: Trigger Point Injection + Home Exercise
Participants will receive myofascial release targeting the cervical and suboccipital muscles once weekly for four sessions. The treatment will focus on the neck muscles as described in the study protocol. Participants will also perform a home exercise program consisting of neck range-of-motion exercises, trapezius stretching, and isometric neck strengthening exercises.
Procedure: Experimental: Myofascial Release + Home Exercise
Participants will receive both trigger point injections using 0.5% lidocaine and myofascial release once weekly for four sessions. Trigger point injections will target active trigger points in the upper trapezius, sternocleidomastoid, and splenius capitis muscles, as appropriate. Myofascial release will be applied to the cervical and suboccipital muscles according to the study protocol. Participants will also perform a home exercise program consisting of neck range-of-motion exercises, trapezius stretching, and isometric neck strengthening exercises.
Procedure: Combined Trigger Point Injection and Myofascial Release
Participants will follow a home exercise program for four weeks. The program will include neck range-of-motion exercises, trapezius stretching, and isometric neck strengthening exercises. Participants will be instructed to perform three sets of 10 repetitions daily. Exercise instructions will be demonstrated by a physician and provided in a printed handout.
Behavioral: Home Exercise Program
Participants will receive trigger point injections using 0.5% lidocaine, administered once weekly for four weeks. A volume of 0.5 mL will be injected into each active trigger point, targeting the upper trapezius, sternocleidomastoid, and splenius capitis muscles as clinically appropriate. A maximum of four trigger points will be treated per session, with a maximum total lidocaine dose of 20 mg per session. Participants will also perform a home exercise program consisting of cervical range-of-motion exercises, trapezius stretching, and isometric strengthening exercises, prescribed as three sets of 10 repetitions daily for four weeks.
Participants will receive myofascial release therapy targeting the cervical and suboccipital muscles, administered once weekly for four weeks. Participants will also perform a home exercise program consisting of cervical range-of-motion exercises, trapezius stretching, and isometric strengthening exercises, prescribed as three sets of 10 repetitions daily for four weeks.
Participants will receive combined trigger point injections using 0.5% lidocaine and myofascial release therapy once weekly for four weeks. A volume of 0.5 mL of lidocaine will be injected into each active trigger point, targeting the upper trapezius, sternocleidomastoid, and splenius capitis muscles as clinically appropriate. A maximum of four trigger points will be treated per session, with a maximum total lidocaine dose of 20 mg per session. Myofascial release therapy will target the cervical and suboccipital muscles. Participants will also perform a home exercise program consisting of cervical range-of-motion exercises, trapezius stretching, and isometric strengthening exercises, prescribed as three sets of 10 repetitions daily for four weeks.
Participants will perform a home exercise program for four weeks consisting of cervical range-of-motion exercises, trapezius stretching, and isometric strengthening exercises. The exercises will be prescribed as three sets of 10 repetitions daily throughout the four-week intervention period.
Change in Pain Intensity on the Visual Analog Scale (VAS)
Change in headache pain intensity from baseline to the end of the 4-week treatment period, measured using the Visual Analog Scale (VAS). The change will be compared among the four study groups.
Time frame: Baseline, Week 4 (end of treatment), and Week 8 (1 month after treatment)
Change in Headache-Related Disability Index (HDI) Score
Change in headache-related disability measured using the Headache Disability Index (HDI). Scores will be assessed at baseline, at the end of treatment, and one month after treatment completion.
Time frame: Baseline, Week 4, and Week 8
Change in Headache Impact Test (HIT-6) Score
Change in the impact of headache on daily functioning measured using the Headache Impact Test (HIT-6). Scores will be assessed at baseline, at the end of treatment, and one month after treatment completion.
Time frame: Baseline, Week 4, and Week 8
Change in 12-Item Short Form Health Survey (SF-12) Score
Change in health-related quality of life measured using the 12-Item Short Form Health Survey (SF-12). Scores will be assessed at baseline, at the end of treatment, and one month after treatment completion.
Time frame: Baseline, Week 4, and Week 8
Change in Number of Headache Days per Week
Change in the number of days with headache during the preceding 7 days, recorded in a headache diary. Headache days will be assessed at baseline, at the end of treatment, and one month after treatment completion.
Time frame: Baseline, Week 4, and Week 8
No study locations are listed for this record.
Plan to share: Undecided
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Konya Beyhekim Training and Research Hospital